Exchange: NASDAQ·Updated 07:02 AM EDT
ALT logo

ALTAltimmune Inc

$2.92
$0.06
(2.01%)
Pre-Market
Prev Close $2.98
EarningsAug 11
Mkt Cap$567.86M
Vol843.00

About ALT

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. Its lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
Upcoming Earnings: Q2 '26

Reports: Aug 11Pre-Market

Estimated EPS

-$0.14

Estimated Rev

$0M

$ALT Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.18 up 30.77% YoY • Altimmune expects to initiate its global PERFORMA Phase 3 MASH trial in the second half of 2026. Topline data from the RECLAIM Phase 2 AUD trial is expected in the third quarter 2026.

Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q2 '26
-$0.14
--
--
N/A
Q1 '26
-$0.24
-$0.18
25.71%
BEAT
Q4 '25
-$0.23
-$0.27
-15.38%
MISSED
Q3 '25
-$0.27
-$0.21
22.83%
BEAT
Q2 '25
-$0.34
-$0.27
19.70%
BEAT

Advertisement|Remove ads.

Advertisement|Remove ads.